GSK's Hepatitis B Drug Shows Promise in Phase-Three Trials
GSK has announced that its experimental hepatitis B drug, bepirovirsen, has met primary endpoints in two phase-three trials. The drug, which could potentially offer a functional cure for the disease, is expected to generate peak annual sales exceeding £2 billion.
Insights:
GSK has reported promising results from two phase-three clinical trials of its experimental hepatitis B therapy, bepirovirsen. The announcement, made on January 7, 2026, indicates that the drug met its primary endpoints, paving the way for regulatory applications. This development is particularly significant given the global burden of chronic hepatitis B, which affects over 250 million people and was responsible for more than 1 million deaths in 2022, according to the World Health Organization.
